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Abstract
This study examined whether the strong reinforcing effects of nicotine and changes in
insulin biomarkers observed in diabetic rats are modulated via insulin. A model of diabetes was
employed involving administration of streptozotocin (STZ), which produces hypoinsulinemia in
rats. The present study included vehicle- or STZ-treated rats that received sham surgery or an
insulin pellet. Two-weeks later, the rats were given extended access to intravenous selfadministration (IVSA) of saline or nicotine. Concomitant changes in food intake, water
responses, and body weight were assessed during 12 days of IVSA. After the last session, plasma
levels of insulin, leptin, amylin, and glucagon-like peptide 1 (GLP-1) were assessed using
Luminex® technology. In a separate cohort, phosphorylated insulin receptor substrate-2 (pIRS-2)
and insulin growth factor-1 receptor β (IGF-1Rβ) were assessed in the nucleus accumbens (NAc)
and ventral tegmental area (VTA) of vehicle- or STZ-treated rats that received sham surgery or
an insulin pellet. STZ-treated rats displayed an increase in glucose levels, a decrease in body
weight, and an increase in nicotine, food, and water intake relative to controls. STZ-treated rats
also displayed a decrease in plasma insulin and leptin levels and an increase in amylin and GLP1 levels relative to controls. Importantly, all of the STZ-induced changes in behavior and insulin
biomarkers were prevented by insulin supplementation. STZ-treated rats also displayed a
decrease in pIRS-2 and IGF-1Rβ in the NAc (but not VTA), an effect that was also prevented by
insulin. These data suggest that insulin systems in the NAc modulate the strong reinforcing
effects of nicotine in male diabetic rats.
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Chapter 1: Introduction
1.1 Tobacco use is a public health concern
According to the Centers for Disease Control (CDC) and the World Health Organization
(WHO), tobacco use is the leading cause of preventable death and disease in the United States.
With approximately 1.1 billion smokers worldwide, nearly 439,000 persons in the United States
and 6 million people worldwide experience tobacco-related deaths every year (CDC, 2014;
WHO, 2011). The WHO has predicted that by 2030, tobacco use will cause an estimated 9
million deaths per year (WHO, 2011). Approximately 16 million people in the United States live
with a disease that is caused by smoking, such as heart and/or cardiovascular disease and various
types of cancer (CDC, 2014).
1.2 Tobacco use in persons with diabetes
There is growing evidence that patients with diabetes display a higher propensity for
tobacco use than the general population. For example, patients with Type 1 diabetes report
higher rates of current smoking (12.3%) than non-diabetic smokers (8.6%; Bishop et al., 2009).
Also, patients with diabetes report lower quit rates and display a greater concern for weight gain
if they quit smoking as compared to non-diabetic smokers (Gill, Morgan, & MacFarlane, 2005).
Patients with diabetes also experience more intense negative affective states and depression
symptoms during smoking abstinence (Haire-Joshu et al., 1994; Spangler et al., 2006).
Unfortunately, patients with diabetes that smoke also experience greater mortality rates and
health complications, such as disrupted glucose homeostasis (Scemama et al., 2006; Tonstad,
2009). Despite the magnitude of the problem associated with diabetes and smoking, the
underlying mechanisms that promote tobacco use among patients with diabetes remain unknown.
Given that the etiological origin of diabetes involves a lack of insulin signaling, the possibility
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exists that a disruption in insulin systems results in greater rewarding effects of nicotine, the
main psychoactive compound that motivates tobacco use.
1.3 Rodent model of diabetes
Diabetes causes metabolic complications and an elevation in blood glucose levels via a
decrease in insulin production from β-cells in the pancreas (Type 1 diabetes) or development of
insulin resistance (Type 2 diabetes). Prior work in our laboratory has examined the behavioral
effects of nicotine in a rodent model of diabetes involving administration of streptozotocin (STZ)
(Pipkin et al., 2017; O’Dell et al., 2014). STZ is taken up by glucose transporters, and this drug
displays the highest affinity for type 2 transporters that are prevalent in the pancreas. When STZ
is administered to rodents, DNA methylation induces cellular toxicity to the insulin-producing βcells of the pancreas (Lenz, 2008). The disruption of insulin release from the pancreas mimics
the etiology of Type 1 diabetes and later stages of Type 2 diabetes.
1.4 Previous work leading to my Master’s Thesis
Previous work in our laboratory has revealed that STZ-treated rats display greater
nicotine intake compared to healthy controls in a rodent model involving 23-hour access to
intravenous self-administration (IVSA; O’Dell et al., 2014). Consistent with the latter finding, a
subsequent report revealed that STZ-treated rats display a more robust conditioned place
preference (CPP) produced by nicotine as compared to healthy control rats (Pipkin et al., 2017).
These studies suggest that a lack of insulin leads to an increase in the rewarding effects of
nicotine. Previous work has also shown that insulin-associated metabolic proteins, including
amylin, GLP-1, leptin, and insulin cross the blood-brain barrier and modulate motivated behavior
(Ferrario et al., 2016; Narayaman, Guarnieri, & DiLeone, 2010; Figlewicz et al., 2003; MietlickiBaase et al., 2015). To examine the role of insulin in modulating the behavioral and biochemical
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effects of nicotine, the present study assessed changes in an array of insulin-related biomarkers
following chronic nicotine IVSA in diabetic rats that received insulin supplementation.
1.5 Potential brain mechanisms
It is well known that the rewarding effects of nicotine are modulated via dopamine
transmission in the mesolimbic pathway, which originates in the VTA and terminates in several
forebrain structures including the NAc (Koob, 2000; Koob & Kreek, 2007; Mansvelder et al.,
2003). It is well established that nicotine produces behavioral effects via activation of nicotinic
acetylcholine receptors (nAChRs) in the brain. nAChRs consist of pentameric membrane
proteins of homomeric or heteromeric α or β receptor subunit complexes. In the presence of
nicotine, the various α or β nAChR subunits leads to distinct channel activation and/or
desensitization. There are an array of different nAChRs located on the excitatory and inhibitory
inputs to the VTA that regulate dopamine release in the mesolimbic pathway. Three major cell
types exist in the VTA that express nAChRs, including including dopamine terminals, gammaaminobutyric acid (GABA) interneurons and glutamate inputs from the prefrontal cortex (Xu et
al., 2006; Mansvelder & McGehee, 2002; Johnson et al., 1992; Kalivas et al., 1989; Kalivas et
al., 1993; Mansvelder et al., 2003). Dopamine cell bodies in the VTA express α2-10 and β2-4
nAChRs subunits (Mansvelder et al., 2003). Glutamate terminals in the VTA express α7
nAChRs and GABAergic interneurons express α4β2 sites. Following administration of nicotine,
α4β2 sites on VTA GABA neurons quickly desensitize (Mansvelder et al., 2002). As a result,
VTA dopamine neurons receive less inhibition from GABA due to the desensitization of α4β2
sites. This effect of nicotine produces a reduction in inhibitory tone that results in enhanced
activiation of dopamine neurons. Nicotine also binds to α7 nAChRs on glutamate terminals, and
these receptors quickly sensitize following nicotine administration (Wooltorton et al., 2003). As
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a result, nicotine produces a shift in tonic inhibition towards excitation of VTA dopamine
neurons that results in enhanced dopamine transmission in the NAc. Overall, desensitization of
the α4β2 sites on VTA GABA neurons leads to disinhibition of dopamine neurons thereby
facilitating a more sustained increase in the release of dopamine in the NAc following nicotine
administration.
Previous studies have revealed that there is a large distribution of insulin receptors in the
NAc and the VTA that modulate motivated behavior (Figlewicz et al., 2003; Havrankova, Roth,
& Brownstein, 1978; Unger, Livingston, & Moss, 1991). There are insulin receptors on
cholinergic interneurons in the NAc, providing a mechanism by which changes in insulin
signaling may influence the behavioral effects of nicotine (Stouffer et al., 2015). Within the
NAc, STZ-treated rats display a down-regulation of pIRS-2 and an up-regulation of protein
kinase B, an insulin-related marker coupled to pIRS-2 receptors (O’Dell & Nazarian, 2016). It is
presently unclear whether STZ-treated rats display a change in insulin-signaling proteins in the
NAc and/or VTA that promotes the rewarding effects of nicotine in diabetic rats.
1.6 Master’s thesis experiments
The present study examined the role of insulin in modulating the strong rewarding effects
of nicotine previously observed in STZ-treated rats. It was hypothesized that insulin
supplementation would reduce the strong reinforcing effects of nicotine to control levels in STZtreated rats. This hypothesis was based on the recent finding that STZ-treated rats display an
increase in CPP produced by nicotine that was reduced to control levels following insulin
supplementation (Íbias, O'Dell, & Nazarian, 2018). Also, an intracranial self-stimulation study
revealed that STZ-treated rats display a decrease in brain reward function that was reduced to
control levels following insulin supplementation (Ho et al., 2012). It was also expected that STZ-
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treated rats would display a decrease in insulin signaling in the NAc given a previous study
showing that STZ-treated rats displayed a reduction in pIRS-2 in the NAc (O’Dell & Nazarian,
2016).
Aim 1: Determine whether insulin modulates the strong reinforcing effects of nicotine and
changes in biomarkers of metabolic syndrome in a rodent model of diabetes.
Aim 2: Determine whether insulin normalizes changes in insulin biomarkers in the NAc and
VTA in a rodent model of diabetes.
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Chapter 2: Methods and Materials
2.1 Subjects
Adult male rats were derived from an out-bred stock of Wistar rats that were maintained
on a 12-hour light/dark cycle (lights off at 6:00 PM and on at 6:00 AM) in a humidity- and
temperature- controlled vivarium (22◦ C). Between postnatal day 52-60, the rats were handled
and weighed for 3-5 days prior to the start of the experiments. The animals had ad libitum access
to food and water prior to IVSA testing, and they were allowed to operant respond for food and
water without limitations during the IVSA sessions. All procedures were approved by the UTEP
Institutional Animal Care and Use Committee.
2.2 Overall experimental design
Below is a summary diagram of the overall experimental timeline.

This report consists of 2 studies that were conducted in separate cohorts of rats. Study 1
employed extended IVSA procedures to examine whether STZ-treated rats display an increase in
6

nicotine intake that is reduced to control levels following insulin supplementation. Specifically,
Study 1 compared nicotine IVSA in vehicle-treated (n=17), STZ-treated (n=16), and STZ-treated
+ insulin (n=13) rats. To examine the role of insulin on nicotine IVSA in the absence of STZ, a
separate group of vehicle-treated rats received insulin supplementation (n=8). This study also
included vehicle-treated rats that received saline IVSA (n=10). Changes in food intake, water
responses, and body weight were assessed each day of IVSA. Twenty-four hours after the last
IVSA session, metabolic biomarkers were assessed in plasma collected from a subset of rats
from Study 1. Study 2 employed protein analysis procedures to assess changes in insulin
biomarkers in the NAc and VTA of STZ-treated rats that received insulin supplementation.
Specifically, Study 2 compared insulin-signaling proteins in nicotine naïve vehicle-treated (n=6),
STZ-treated (n=6), or STZ-treated + insulin (n=5-6) rats. Brain tissue was collected 2 weeks
after STZ administration to examine protein markers at a time point that corresponded to the
onset of nicotine IVSA in Study 1.
2.3 Diabetes induction and insulin supplementation
Rats received vehicle or STZ administration (45 mg/kg, s.c.). STZ was dissolved in
citrate buffer (0.1 M citric acid and 0.1 M sodium citrate; Sigma-Aldrich, St. Louis, MO, USA).
The dose of STZ was selected based on previous work demonstrating that this concentration
produces a rapid and reliable increase in glucose levels 3-5 days after STZ administration (Pipkin
et al., 2017; O’Dell et al., 2014). Immediately after vehicle or STZ administration, the rats were
anesthetized with an isoflurane/oxygen vapor mixture (1-3%) and received a sham surgery or
implanted subcutaneously with 2 insulin pellets based on the manufacturer specifications for the
weight (Linplant® Toronto, ONT, CA). According to the manufacturer, each pellet releases 2
U/24 hours, consistent with physiological levels in humans. Also, the pellets are purported to
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release insulin for at least 60 days, which exceeds our experimental timeline. Indeed, Table 1
illustrates that the insulin pellets maintain control levels of glucose in STZ-treated rats
throughout IVSA testing. Plasma glucose levels were assessed approximately every 2-3 days
using a glucose meter calibrated for rodent plasma (AlphaTRAK® Abbott Park, IL, USA). A
lancet was used to prick the tip of the tail to extract a small drop of blood that was placed on a
glucose test strip. For both studies, the rats were tested 2 weeks after vehicle or STZ
administration and insulin supplementation.
2.4 Study 1 methods
Study 1 examined the effects of insulin on the reinforcing effects of nicotine and changes
in plasma metabolic biomarkers in vehicle- and STZ-treated rats. The rats were tested in operant
chambers that were housed inside sound-attenuated ventilated cubicles (Med Associates, St.
Albans, VT, USA). During IVSA testing, the rats lived in a dedicated operant chamber for 23
hours per day. The rats were removed daily from the chambers for 1 hour (11:00 AM-12:00 PM)
to clean the chambers, retrieve the data, and replenish the food and water levels. During that 1hour period, the rats were placed into a home cage in the same testing room, and they were given
ad libitum access to food and water.
Prior to IVSA testing, the rats were trained to perform operant responses for food and
water for 4-5 days on a fixed ratio (FR) 1 schedule of reinforcement. The total number of food
and water operant responses were recorded daily for each rat. The rats were allowed to nosepoke in a food receptacle that delivered palatable chow from a pellet dispenser (45 mg/kg; BioServ, Frenchtown, NJ, USA). The rats also performed nose-poke responses in a separate hole
located in the opposite side of the food pellet dispenser and levers. Each nose poke dispensed 0.1
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mL of water into an adjacent dipper cup via a syringe pump. All rats reached stable levels of
responding for food and water the initial 1-2 days of food and water training.
The rats were then returned to their home cage and allowed to free feed the day before
the catheterization surgery. The rats were anesthetized using an isoflurane/oxygen vapor mixture
(1-3%) and were then prepared with IV catheters into the jugular vein, as previously described
O’Dell et al., 2014; Flores et al., 2016; Natividad et al., 2013). After surgery, the rats were
allowed to recover for 4 days in their home cage where they were given ad libitum access to food
and water. The catheters were flushed daily (0.3-0.5 mL) with an antibiotic solution containing
Cefazolin® dissolved in saline and heparin (30 USP units/mL).
Two-weeks after STZ administration, the rats were given extended access to saline or
nicotine by introducing 2 novel levers (active and inactive) on the first IVSA session. The
rationale for the delay in testing after STZ was based on a prior study showing that 2 weeks after
STZ administration, diabetic rats display a profound and dose-dependent increase in nicotineinduced CPP (Pipkin et al., 2017) and IVSA (O’Dell et al., 2014). Presses on the active lever
delivered 0.1 mLs of saline or nicotine via a syringe pump. Responses on the active lever
delivered nicotine on a FR-1 schedule of reinforcement. Each response on the active lever
illuminated a 28 V cue light above the lever at the onset of the 1 second infusion, and the cue
light was terminated after a 20 second time-out period. Presses on the active lever during the
time-out period had no scheduled consequences. (−) Nicotine hydrogen tartrate salt (SigmaAldrich, St. Louis, MO, USA) was dissolved in 0.9% sterile saline and adjusted to 7.4 pH. The
nicotine solutions were prepared every day and adjusted to the rats’ body weight from the
previous day. The doses of nicotine were selected based on previous work using 23-hour access
to nicotine IVSA (O’Dell et al., 2007; O’Dell & Koob, 2007), The latter studies revealed dose-
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dependent differences in nicotine IVSA that remain stable across 40 days. Also, previous work
revealed that nicotine intake is increased following intermittent periods of drug abstinence,
referred to as the “nicotine deprivation effect.” Thus, in the present study each dose of nicotine
was available for 4 consecutive days with 3 intervening days of forced abstinence prior to
initiating the next higher dose of nicotine. Three animals were removed from our final analysis
that were leaking from the exit port of the IV catheter, 1 rat was removed due to a faulty active
lever, and 8 STZ-treated rats were eliminated that displayed glucose levels greater than 700
mg/dl or were too sick to continue behavioral testing.
Twenty-four hours after the last IVSA session, the rats were sacrificed and trunk blood
was collected to assess changes in plasma metabolic biomarkers. The blood was centrifuged for
15 minutes at 6,900 rpm at 4°C. The plasma was extracted and stored at -80°C until assayed
using commercially available MilliPlex® kits (Millipore Sigma, MA, USA) specific for insulin,
leptin, amylin, and GLP-1. The plates were analyzed on a MAGPIX® system using xPONENT®
software. The MAGPIX® system was calibrated before each assay using calibration and
performance verification kits (Luminex Corporation Inc. Austin, TX, USA).
2.5 Study 2 methods
Study 2 assessed changes in insulin-signaling proteins in the NAc and VTA of vehicleand STZ-treated rats that received insulin supplementation. This study was conducted in nicotine
naïve rats in order to assess the effects of insulin in the absence of any confounding effects
produced by chronic nicotine exposure. Two-weeks after vehicle or STZ administration, the rats
were sacrificed and the NAc and VTA were dissected from vehicle-, STZ-, and STZtreated+insulin rats. The tissue was flash frozen and stored at -80°C until assayed. The tissue was
homogenized in lysis buffer containing 10 mM HEPES, 10 mM KCl, 1.5 mM MgCl2, 1% Igepal
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(Sigma-Aldrich, St. Louis, MO, USA) dissolved in a protease and phosphatase inhibitor cocktails
(Roche, Indianapolis, IN, USA), as previously described (Ramos et al., 2017). The tissue
homogenates were then centrifuged at 4°C for 5 minutes at 14,000 rpm, and the resultant
supernatant was collected. Protein concentrations (25 ug) were quantified from the cytosol using
a Bio-Rad Protein Assay Standard II Kit with bovine serum albumin as the standard solution
(Bio-Rad Laboratories, Hercules, CA, USA). Insulin-signaling proteins were separated via SDSPAGE then transferred to nitrocellulose membranes (pIRS-2) or PVDF (IGF-1Rβ).
Nitrocellulose membranes and PVDF were blocked in 5% non-fat dry milk dissolved 1X-trisbuffered saline containing tween 20 (1X-TBST; Cell-Signaling Technology Inc. Danvers, MA,
USA). Primary antibodies specific for pIRS-2 (186kDa; 1:2000) and IGF-1Rβ (95kDa; 1:2000)
were incubated in 5% non-fat dry milk dissolved in 1X-TBST and probed overnight at 4°C.
Subsequently, membranes were repeatedly washed in 1X-TBST and re-probed for corresponding
HRP-conjugated secondary antibodies specific for anti-mouse IgG (1:10000) and anti-rabbit IgG
(1:10000). Membranes were imaged on a ChemiDocTM XRS+ in chemiluminescent reagents for
protein intensity. All blots were normalized to α-tubulin (52kDa; 1:6000) and analyzed using
ImageJ software provided by NIH.
2.6 Statistics
Three-way mixed-measures analysis of variance (ANOVA) were used to analyze intake,
infusions, active lever presses, and inactive lever presses (Figure 1) as well as food intake, water
responses, and changes in body weight (Figure 2). For the behavioral analyses, treatment was the
between-subject factor and dose (saline or escalating doses of nicotine) and day were withinsubject factors. For the behavioral results, test for assumptions of multiple sphericity were
applied using the Huynh-Feldt correction factor. As a result, appropriate corrections were applied
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to the degrees of freedom resulting in more conservative F-ratios for the behavioral measures.
For the glucose analysis of Study 1, a 2-way mixed-measures ANOVA was used with treatment
as a between-subject factor and time as a within subject factor (prior to IVSA versus after the last
day of IVSA). For the glucose analysis of Study 2, a 1-way ANOVA was used with treatment as
a between-subject factor (Table 1). For each metabolic biomarker, separate 1-way ANOVAs
were used with treatment as a between-subject factor (Figure 3). For the insulin-signaling
proteins, 2-way ANOVA was used with treatment and brain region (NAc or VTA) as betweensubject factors. Post-hoc analyses compared group differences following significant interaction
effects collapsed across day or dose depending on which main effects were observed using
Fisher’s LSD test, (p≤0.05).
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Chapter 3: Results
3.1 Analysis of glucose levels
Table 1 illustrates mean (+SEM) plasma glucose levels. For Study 1, the initial analysis
of glucose levels revealed that there was no interaction between treatment and time [F(4,59)=0.54,
p=0.71]. However, this analysis revealed a main effect of treatment [F(4,59)=183.2, p≤0.0001],
with STZ-treated rats displaying higher glucose levels as compared to all other groups both prior
to and at the end of IVSA (†p≤0.01). Vehicle-treated rats that received insulin displayed lower
glucose levels than their respective vehicle-treated rats that pressed for nicotine (*p≤0.01),
suggesting that the insulin regimen produced a degree of hypoglycemia in healthy animals. For
Study 2, the analysis revealed a main effect of treatment [F(2,14)=137.2, p≤0.0001], with STZtreated rats displaying higher glucose levels than all other groups (†p≤0.01). Importantly, in both
Study 1 and 2, STZ-treated rats that received insulin displayed similar glucose levels relative to
their respective vehicle-treated controls.
3.2 Analysis of saline or nicotine IVSA
Figure 1 illustrates mean (±SEM) intake, infusions, active lever presses, and inactive
lever presses. The initial analysis of daily intake (panel A) revealed that there was no interaction
between treatment, dose, and day [F(17.1,252.4)=1.12, p=0.32]. However, this analysis revealed a
significant interaction between treatment and dose [F(7.6,113.5)=4.23, p<0.0001]. Thus, the panel
on the right reflects intake collapsed across day. Post hoc analyses revealed that all groups that
pressed for nicotine displayed higher intake as compared to vehicle-treated rats that pressed for
saline (*p<0.01). Importantly, STZ-treated rats displayed higher levels of intake at each dose of
nicotine as compared to all other groups (†p<0.05). There were no significant differences in
nicotine intake between vehicle- and STZ-treated+insulin groups.
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The analysis of infusions (panel B) revealed that there was no interaction between
treatment, dose, and day [F(20.0,296.1)=1.15, p=0.30]. However, there was a main effect of
treatment [F(4,59)=17.34, p<0.0001]. Thus, the panel on the right reflects infusions collapsed
across dose and day. Post hoc analyses revealed that all groups that pressed for nicotine
displayed more infusions as compared to vehicle-treated rats that pressed for saline (*p<0.01).
Importantly, STZ-treated rats displayed more nicotine infusions as compared to all other groups
(†p<0.05). There were no differences in the number of nicotine infusions between vehicle- and
STZ-treated+insulin groups.
The analysis of active lever presses (panel C) revealed that there was no interaction
between treatment, dose, and day [F(18.1,267.6)=0.48, p=0.97]. However, there was a main effect of
treatment [F(4,59)=20.45, p<0.01]. Post hoc analyses revealed that both vehicle-treated groups that
pressed for nicotine displayed more active lever presses as compared to the vehicle-treated group
that pressed for saline (*p<0.01). Importantly, STZ-treated rats displayed more active lever
presses for nicotine as compared to all other groups (†p<0.05). There were no differences in
active lever presses between vehicle- and STZ-treated+insulin groups. The analysis of inactive
lever presses (panel D) revealed that there was no interaction between treatment, dose, and day
[F(18.1,268.0)=0.57, p=0.92]. There were also no main effects of treatment [F(4,59)=1.63, p=0.18] or
dose [F(1.6,98.8)=0.75, p=0.69].
3.3 Analysis of food, water, and weight
Figure 2 illustrates mean (±SEM) food intake, water responses, and weight change. The
analysis of food intake (panel A) revealed that there was no interaction between treatment, dose,
and day [F(21.1,312.6)=0.61, p=0.91]. However, there was a main effect of treatment [F(4,59)=14.56,
p<0.01]. Post hoc analyses revealed that vehicle- and STZ-treated+insulin groups that pressed
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for nicotine displayed less food intake as compared to vehicle-treated controls that pressed for
saline (*p<0.01), an effect that illustrates the food suppressant effects of nicotine. Importantly,
STZ-treated rats displayed higher levels of food intake as compared to all other groups
(†p<0.05). There were no differences in food intake between vehicle- and STZ-treated+insulin
groups. The analysis of water responses (panel B) revealed that there was no interaction between
treatment, dose, and day [F(11.5,170.7)=1.04, p=0.41]. However, there was a main effect of
treatment [F(4,59)=6.31, p<0.0001]. Post hoc analyses revealed that STZ-treated rats displayed
more water responses than all other groups (†p<0.05). There were no differences in water intake
between vehicle- and STZ-treated+insulin groups.
Weight change was calculated by subtracting daily body weight from values collected on
the first day of IVSA, such that positive values reflect an increase and negative values reflect a
decrease in body weight from the first day of IVSA. The analysis of weight change (panel C)
revealed that there was no interaction between treatment, dose, and day [F(21.0,311.0)=1.15,
p=0.29]. However, there was a main effect of treatment [F(4,59)=16.84, p<0.0001]. Post hoc
analyses revealed that vehicle-treated rats that pressed for saline displayed greater increases in
body weight as compared to vehicle-, STZ-, and STZ-treated+insulin rats that pressed for
nicotine (*p<0.01), an effect that illustrates the weight suppressant effects of nicotine.
Importantly, STZ-treated rats displayed lower body weights relative to all other groups
(†p<0.05). There were no differences between vehicle- and STZ-treated+insulin groups.
3.4 Analysis of insulin biomarkers
Figure 3 illustrates mean plasma levels (±SEM) of insulin, leptin, amylin, and GLP-1.
The analysis of insulin (panel A) revealed a main effect of treatment [F(4,43)=8.62, p<0.0001].
Post hoc analysis revealed that STZ-treated rats displayed lower levels of insulin as compared to
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all other groups (†p<0.0001). There was no difference between the vehicle- and STZ-treated +
insulin groups. The analysis of leptin (panel B) revealed a main effect of treatment [F(4,43)=11.62,
p<0.0001]. STZ-treated rats displayed lower levels of leptin as compared to all other groups
(†p<0.0001). There were no differences in leptin levels between vehicle- and STZtreated+insulin groups. The analysis of amylin (panel C) revealed a main effect of treatment
[F(4,43)=5.43, p<0.001]. STZ-treated rats displayed higher levels of amylin than their respective
vehicle-treated controls that pressed for nicotine (#p<0.0001), an effect that illustrates STZinduced enhancement of amylin levels. Also, vehicle-treated rats that received insulin displayed
higher amylin levels than vehicle-treated rats that pressed for nicotine (#p<0.0001), suggesting
that our insulin regimen increased amylin levels. There were no differences in amylin levels
between vehicle- and STZ-treated+insulin rats. The analysis of GLP-1 (panel D) revealed a main
effect of treatment [F(4,43)=3.83, p<0.01]. STZ-treated rats displayed higher levels of GLP-1 than
vehicle-treated rats that pressed for nicotine (#p<0.01), an effect that illustrates STZ-induced
increases in GLP-1 levels. Also, vehicle-treated rats that received insulin displayed an increase in
GLP-1 levels as compared to vehicle-treated rats that pressed for nicotine (#p<0.0001),
suggesting that insulin enhanced GLP-1 levels alone. There were no differences in GLP-1 levels
between vehicle- and STZ-treated+insulin rats.
3.5 Analysis of insulin-signaling proteins
Figure 4 illustrates mean protein levels (±SEM) of pIRS-2 and IGF-1Rβ in the NAc and
VTA. The analysis of pIRS-2 revealed a significant interaction between treatment and brain
region [F(2,28)=16.46, p<0.0001]. In the NAc (panel A), post-hoc analysis revealed that STZtreated rats displayed lower levels of pIRS-2 as compared to all other groups (†p<0.0001). There
was no difference in pIRS-2 levels between vehicle- and STZ-treated+insulin rats. In the VTA
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(panel B), post-hoc analysis revealed that both groups of STZ- and STZ-treated+insulin rats
displayed higher levels of pIRS-2 as compared to vehicle-treated controls (*p<0.0001). Also,
STZ-treated+insulin rats displayed higher levels of pIRS-2 as compared to STZ-treated rats
(#p<0.0001), suggesting that insulin produced a further enhancement of pIRS-2 levels in the
VTA.
The analysis of IGF-1Rβ revealed a significant interaction between treatment and brain
region [F(2,29)=5.31, p<0.01]. In the NAc (panel C), post-hoc analysis revealed that STZ-treated
rats displayed lower levels of IGF-1Rβ as compared to all other groups (†p<0.0001). There was
no difference in IGF-1Rβ levels between vehicle- and STZ-treated+insulin rats. In the VTA
(panel D), post-hoc analysis revealed that STZ-treated+insulin rats displayed higher levels of
IGF-1Rβ as compared to vehicle-treated controls (*p<0.0001).
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Chapter 4: Discussion
4.1 Summary
The present study revealed that STZ-treated rats displayed an increase in plasma glucose
levels, body weight, food intake, and water responses. The pattern of changes in these measures
was prevented in STZ-treated rats that also received insulin, consistent with another report using
the same insulin supplementation procedure (Sevak et al., 2007). The finding that insulin
prevented STZ-induced increases in glucose levels, food intake, and water responses to vehicletreated control levels provides verification of the induction and reversal of hypoinsulinemia, a
hallmark physiological effect of diabetes. The major finding of Study 1 was that STZ-treated rats
displayed greater reinforcing effects of nicotine relative to vehicle-treated rats, and this effect
was reduced to control levels in STZ-treated rats that also received insulin. STZ-treated rats also
displayed a decrease in insulin and leptin and an increase in amylin and GLP-1 plasma levels,
and the pattern of these changes was reduced to control levels in STZ-treated rats that received
insulin. STZ-treated rats also displayed a decrease in pIRS-2 and IGF-1Rβ levels in the NAc, and
this pattern of changes was also reduced to control levels in STZ-treated rats that received insulin
supplementation. Also, STZ-treated rats that received insulin supplementation displayed an
increase in pIRS-2 and IGF-1Rβ levels in the VTA, suggesting that an enhancement of insulin
systems in the VTA may have promoted the behavioral effects observed in this group.
4.2 Reinforcing effects of nicotine
The present study revealed that STZ administration enhanced nicotine IVSA across a
range of doses as compared to vehicle-treated rats, consistent with previous research from our
laboratory using extended access to nicotine IVSA procedures (O’Dell et al., 2014). The notion
that STZ enhances the rewarding effects of nicotine is consistent with previous work showing
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that STZ enhances CPP produced by nicotine (Pipkin et al., 2017), an effect that is normalized to
control levels following insulin supplementation (Íbias et al., 2018). Previous research has also
revealed that insulin-resistant rats that were fed a high fat diet (HFD) displayed greater CPP
produced by nicotine as compared to non-insulin resistant rats that received the HFD regimen
(Richardson et al., 2014). Together, these findings suggest that a lack of insulin signaling
enhances the reinforcing effects of nicotine.
4.3 Insulin biomarkers
STZ administration altered plasma metabolic biomarkers, and the pattern of changes in
these biomarkers was reduced to control levels following insulin supplementation. Specifically,
STZ-treated rats displayed a decrease in insulin and leptin, consistent with a previous report
showing that STZ administration blunted insulin and leptin release (Havel et al., 1998). Given
the role of insulin and leptin in regulating satiety and consummatory behaviors, the reduction in
insulin and leptin likely contributed to the increase in food intake and water responses observed
in STZ-treated rats (Figlewicz & Sipols, 2010; Stice et al., 2012). STZ-treated rats also displayed
an increase in amylin and GLP-1 levels as compared to vehicle-treated rats. The direction of
these changes is consistent with the anorectic effects of amylin, as administration of this
metabolic biomarker has been shown to induce weight loss in rodents (Mietlicki-Baase et al.,
2015). Moreover, long-term administration of amylin or an amylin agonist induces weight loss
(Mietlicki-Baase et al., 2015; Lutz, 2012). With regard to GLP-1, this hormone stimulates the
synthesis and secretion of insulin (Lee & Jun, 2014) and elevated levels of GLP-1 are associated
with weight loss (Keleidari et al., 2018; Koliaki & Doupis, 2011). Plasma levels of GLP-1 also
increase following food consumption, and the release of GLP-1 prevents pancreatic β-cell death
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(Keleidari et al., 2018). Thus, it is possible that STZ-treated rats displayed higher levels of GLP1 in response to lower levels of plasma insulin.
4.4 Insulin in the mesolimbic system
The changes in insulin-signaling proteins were focused in the NAc, a terminal region of
the mesolimbic reward pathway. Specifically, STZ-treated rats displayed a down-regulation of
NAc pIRS-2 and IGF-1Rβ levels that were returned to control levels in STZ-treated rats that
received insulin. Consistent with previous findings, STZ-treated rats displayed a decrease in
pIRS-2 levels in the NAc relative to controls (O’Dell & Nazarian, 2016). Previous work has also
shown that STZ administration decreases IRS-2 signaling in the hippocampus (Li et al., 2002;
Gomes et al., 2009) and hypothalamus (Gelling et al., 2006), an effect that was returned to
control levels following viral-mediated over-expression of IRS-2 levels. Interestingly, the levels
of pIRS-2 and IGF-1Rβ were increased in the VTA of STZ-treated rats that received insulin
relative to vehicle-treated controls, suggesting that the insulin supplementation regimen
stimulated pIRS-2 and IGF-1Rβ signaling in the VTA. Together, these findings suggest that the
strong reinforcing effects of nicotine observed in STZ-treated rats are modulated via insulin
systems in the NAc.
A critical common denominator in metabolic signaling downstream of the actions of
insulin, leptin and GLP-1 are their effects on blood glucose levels and the resulting decrease in
glucose levels upon insulin treatment.

Glucose has been shown to have direct effects on

increasing and decreasing mesolimbic dopamine neuronal activity in a concentration dependent
manner (Levin, 2000). Glucose is also capable of producing rewarding effects independent of its
sweet taste, as evident by CPP evoked following intragastric glucose administration (Ren et al.,
2010). In fact, recent work in our laboratory has shown that the strong rewarding effects of
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nicotine observed in STZ-treated rats can be attenuated by direct normalization of blood glucose
levels with dapagliflozin, a sodium-glucose type 2 cotransporter inhibitor (Íbias et al., 2018)
Importantly, a prior study revealed that administration of a GLP-1 receptor agonist (Exendin-4)
reduces nicotine-induced CPP, locomotor activity, and increases in NAc dopamine release
compared to controls (Egecioglu, Engel, & Jerlhag, 2013). Also, administration of a GLP-1
agonist into the interpeduncular nucleus reduces nicotine IVSA as compared to controls (Tuesta
et al., 2017). Also, viral-mediated gene activation of GLP-1 neurons in the nucleus tractus
solitarius has been shown to reduce nicotine IVSA as compared to controls (Tuesta et al., 2017).
The latter study also demonstrated that viral-mediated knockdown of GLP-1 receptors in the
medial habenula promotes nicotine IVSA compared to controls. The latter findings along with
the present results suggest that the rewarding effect of nicotine are enhanced in diabetic rodents
via a complex interplay of different metabolic factors.
It has been hypothesized that the high propensity of tobacco use among patients with
diabetes is modulated via reduced dopamine transmission in the mesolimbic pathway [see 20].
Indeed, dampened dopaminergic systems may promote other compulsive behaviors, such as
overeating (Blum et al., 2000, 2008; Fineberg et al., 2010). It is possible that the lack of insulin
produced by diabetes suppresses dopamine systems in a manner that promotes tobacco use in an
attempt to increase dopamine transmission. In line with this suggestion, STZ-treated rats display
higher brain reward thresholds than healthy controls using intracranial self-stimulation
procedures, an indication of a reward deficiency syndrome (Ho et al., 2012). The latter effect
was normalized to control levels following insulin supplementation. The manner in which a
disruption in insulin signaling produced by diabetes alters dopamine systems is unclear.
However, recent evidence suggests that insulin facilitates dopamine transmission via cholinergic
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interneurons in the NAc (Stouffer et al., 2015). The latter study demonstrated that insulin
administration enhances dopamine release in NAc indirectly via activation of insulin receptors
expressed on cholinergic interneurons. Thus, it is possible that diabetes reduces insulin receptor
activation in striatal cholinergic interneurons, thereby attenuating dopamine release in the NAc.
Indeed, STZ-treated rats display a reduction in nicotine-induced dopamine release in the NAc
(O’Dell et al., 2014). STZ-treated rats also displayed an up-regulation of dopamine transporters
(DAT) in the NAc, an effect that is likely related to greater clearance of extracellular dopamine
in STZ-treated rats. STZ-treated rats also displayed a larger down-regulation of dopamine D1receptors in the NAc as compared to controls, an effect that is likely due to chronic low levels of
dopamine observed in STZ-treated rats (O’Dell et al., 2014).
4.5 Other drugs of abuse
Prior studies have produced mixed results with regard to the rewarding effects of drugs of
abuse other than nicotine in STZ-treated rats. For example, STZ-treated rats display similar
levels of cocaine IVSA as compared to vehicle-treated rats (Galaci et al., 2003). However, STZtreated rats display a reduction in the magnitude of cocaine-induced CPP relative to vehicletreated rats (Kamei & Ohsawa, 1997). STZ-treated rats display less amphetamine IVSA relative
to vehicle-treated rats (Galici et al., 2003; Sevak et al., 2008). The latter study also found no
differences in the magnitude of amphetamine-induced CPP in vehicle- versus STZ-treated rats
(Sevak et al., 2008). STZ-treated rats display a larger magnitude of CPP produced by
methamphetamine (Bayat & Haghparast, 2015; Kamei & Ohsawa, 1996) and morphine (Kamei,
Ohsawa, & Suzuki, 1997; Samandari et al., 2013). Previous work has also shown that STZtreated rats display greater sensitivity to the behavioral effects (locomotor activity, catalepsy, and
yawning) of dopamine D2/D3 receptor agonists (Sevak et al., 2007; Sevak, Koek, & France,
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2005). This increase in dopamine receptor sensitivity produced by STZ was reduced to control
levels following insulin supplementation (Sevak et al., 2007). The latter finding is consistent
with the present finding that the pattern of changes in behavior and biological markers induced
by STZ are returned to control levels following insulin supplementation.
4.6 Reduced aversive effects of nicotine
In addition to nicotine reward, the short-term effects of nicotine also include aversive
effects, particularly at high doses of this drug. Previous studies have shown that rats display CPA
for an environment that was previously paired with a high dose of nicotine (Torres et al., 2008).
Also, the aversive effects nicotine have been studied using conditioned taste aversion (CTA)
procedures, where rats avoid a flavor previously paired with a high dose of nicotine. Previous
work has revealed that the aversive effects of nicotine are lower in STZ-treated versus health
control rats (Pipkin et al., 2017). Specifically, the latter report found that STZ-treated rats display
reduced CPA following administration of a high dose of nicotine as compared to healthy
controls. The present finding suggests that STZ-treated rats display strong rewarding effects of
nicotine that are insulin mediated. Future studies are needed to examine whether the lack of
aversive effects of nicotine is insulin mediated, and whether reduced aversive effects of nicotine
promotes tobacco use in persons with diabetes.
4.7 Other considerations
The possibility exists that STZ produces an array of biological consequences that may
have influenced our IVSA results. With regard to body weight, the concentration of nicotine was
adjusted daily for each rat in order to account for the reduction in body weight across our
experimental timeline with diabetic rodents. With regard to fluid loss produced by excessive
urination, a previous study revealed that STZ-treated rats displayed lower levels of saline versus
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nicotine IVSA (O’Dell et al., 2014). Thus, it does not appear that STZ-treated rats selfadminister more nicotine in an attempt to increase fluid levels. Another potential consideration is
that STZ-treated rats display tactile allodynia and cataract formation (Morrow, 2004; Wei et al.,
2003), and these effects of STZ could disrupt IVSA behavior. However, the emergence of these
side effects of STZ occurs at a later time point that exceeds our 12-day period of IVSA.
Furthermore, the present study found that STZ-treated rats display robust increases in operant
responding for nicotine, food, and water that do not appear to be altered by the emergence of any
negative effects of STZ. Another important consideration is that vehicle-treated rats that received
insulin displayed a hypoglycemic state below vehicle-treated controls. This effect of insulin
might explain the increases in food intake, weight change, GLP-1, and amylin levels that were
observed in insulin-treated rats. Indeed, GLP-1 levels have been shown to increase in procedures
that enhance food consumption in rodents (Keleidari et al., 2018). Also, administration of amylin
has been shown to produce a hypoglycemic state in healthy mice, suggesting that hypoglycemia
may produce elevated amylin levels in rodents (Guerreiro et al., 2013). Lastly, the possibility
exists that STZ-treated rats may display an altered metabolic rate of nicotine that could influence
our nicotine IVSA results. However, a previous study in our laboratory revealed that STZ-treated
rats display similar plasma levels of the nicotine metabolic cotinine as compared to control rats
(O’Dell et al., 2014).
4.8 Clinical implications
There are several clinical implications to consider from this report. First, these results
suggest that a lack of insulin signaling promotes the strong rewarding effects of nicotine in
patients with diabetes. There are converging lines of evidence suggesting that suppressed insulin
signaling impairs dopamine transmission in both humans and rodent models (O’Dell et al., 2014;
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Carvaggio et al., 2015;Trulson & Himmel, 1983; Lackovic et al., 1990; Kono & Takada, 1994;
Crandall & Fernstorm, 1983; Bitar et al., 1986). Thus, pharmacological interventions that
normalize insulin signaling and dopamine deficits may reduce tobacco use in patients with
diabetes. As a result, maintaining proper glycemic control may be critical for diabetic patients
seeking to reduce drug use and/or smoking behavior. Another rodent study revealed that IRS-2
knockout mice demonstrate impaired insulin signaling and glucose tolerance (Withers et al.,
1998). Thus, pharmacotherapies that facilitate IRS-2 signaling should be considered as potential
tools to reduce the strong rewarding effects of nicotine that may promote tobacco use in patients
with diabetes. Future studies are needed to assess the role of glucose in modulating the rewarding
effects of nicotine, especially given the finding that dapagliflozin (Farxiga®), a sodium-glucose
transport inhibitor normalized CPP produced by nicotine in STZ-treated rats (Íbias et al., 2018).
Also, a recent study revealed that administration of glucophage (Metformin®), a medication used
to treat Type 2 diabetes reduced anxiety-like behaviors produce by nicotine withdrawal in mice
(Brynildsen et al., 2018). It is recognized that different biological consequences may accompany
the absence of insulin versus the insensitivity to insulin. These distinct etiological origins of
Type 1 versus Type 2 diabetes may require different smoking cessation remedies in patients who
suffer from different types of diabetes. Future studies are needed to assess the neurobiological
substrates by which diabetes enhances tobacco use vulnerability in patients with diabetes.
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Table 1. Glucose levels (mg/dL±SEM) across experimental groups that received vehicle or STZ
Study 1: Behavioral analysis
Groups:

IVSA of:

n

Glucose levels
prior to IVSA

Study 2: Protein analysis
Glucose levels
at the end of IVSA

Glucose levels

Groups:

NAc (n)

Vehicle-treated

6

6

137.6±5.0

VTA (n)

Vehicle-treated

Saline

10

Vehicle-treated

Nicotine

17

123.7±2.8

..148.9±10.4

STZ-treated

Nicotine

13

. 515.5±17.1†

.. 505.3±28.4†

STZ-treated

6

6

570.0±23.8†

STZ-treated+insulin

Nicotine

16

116.6±21.8

127.5±25.3

STZ-treated+insulin

5

6

178.5±22.6

Vehicle-treated+insulin

Nicotine

8

77.7±5.9*

86.7±14.5

116.2±6.5

136.0±3.7

The values reflect mean glucose (mg/dL±SEM ) levels that were taken prior to IVSA and at the end of IVSA. †Indicates different from all other groups, and *indicates
different from vehicle-treated rats (p≤0.05).

Table 1.

35

Figure 1. Mean (±SEM) nicotine intake (A), nicotine infusions (B), active lever presses (C), and
inactive lever presses (D) during each day (left panels) and averaged across days (right panels).
The group sizes were as follows: vehicle-treated/Saline IVSA (n=10), vehicle-treated/Nicotine
IVSA (n=17), STZ-treated/Nicotine IVSA (n=16), STZ-treated+insulin/Nicotine IVSA (n=13),
and vehicle-treated+insulin/Nicotine IVSA (n=8). The asterisks (*) denote a significant
difference from vehicle-treated/Saline IVSA rats, and the daggers (†) denote a difference from
all other groups (p≤0.05).

36

Figure 2. Mean (±SEM) food intake (A), water responses (B), and weight change (D) during
each day (left panels) and averaged across days (right panels). The group sizes were as follows:
vehicle-treated/Saline

IVSA

(n=10),

vehicle-treated/Nicotine

IVSA

(n=17),

STZ-

treated/Nicotine IVSA (n=16), STZ-treated+insulin/Nicotine IVSA (n=13), and vehicletreated+insulin/Nicotine IVSA (n=8). The asterisks (*) denote a significant difference from
vehicle-treated/Saline IVSA rats, and the daggers (†) denote a difference from all other groups
(p≤0.05).
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Figure 3. Mean (±SEM) plasma levels of insulin (A), leptin (B), amylin (C), and GLP-1 (D)
collected after the last IVSA session. The daggers (†) denote a significant difference from all
other groups (p≤0.05), and the number signs (#) denote a difference from vehicle-treated rats that
pressed for nicotine.
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Figure 4. Mean (±SEM) protein levels of pIRS-2 (A and B) and IGF-1R (C and D) in the NAc
(left panels) and VTA (right panels). The group sizes were as follows: vehicle-treated (n=6),
STZ-treated (n=6), and STZ-treated+insulin (n=5). The asterisks (*) denote a significant
difference from vehicle-treated rats, and the daggers (†) denote a difference from all other groups
(p≤0.05).
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